fifty-four patients whose disease had been staged as extensive small cell carcinoma of the bronchus were randomised to receive either cav1 ( cyclophosphamide 600 mg m-2 i.v. , adriamycin 50 mg m-2 i.v. , given on day 1 , and etoposide 500 mg m-2 p.o . given on day 3 ) or cav5 ( cyclophosphamide and adriamycin given as for cav1 , etoposide 500 mg m-2 given in divided dose over days 3-7 ) on a 21-day schedule .
C0278726
staged
C0006255
bronchus